| 2006D-0383 | Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases | |||||||||||||||||||||||
| FDA Comment Number : | EC3051 | |||||||||||||||||||||||
| Submitter : | Mr. Edmund A. Keefe | Date & Time: | 12/12/2006 09:12:33 | |||||||||||||||||||||
| Organization : | Mr. Edmund A. Keefe | |||||||||||||||||||||||
| Category : | Individual Consumer | |||||||||||||||||||||||
| Issue Areas/Comments | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| We want the pharmaceutical industry to use only ethical sources for vaccines. Only if no ethical sources are available, and the health needs for the vaccine are critical, can aborted fetal cell lines be used. | ||||||||||||||||||||||||